Why Cubist Pharmaceuticals Inc. Shares Jumped

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Cubist Pharmaceuticals (NASDAQ: CBST  ) , a biopharmaceutical company focused on developing acute-care therapies, advanced by as much as 11% after announcing positive late-stage data for its complicated urinary-tract-infection antibiotic, ceftolozane/tazobactam, also known as CXA-201.

So what: According to Cubist's press release, the antibiotic CXA-201 met the trials' primary endpoint of noninferiority to levofloxacin, which entailed a "microbiological eradication and clinical cure rate five to nine days after the end of therapy." Cubist also notes that while the trial wasn't designed to test the superiority of its antibiotic, a secondary analysis would suggest the potential for superiority over levofloxacin.

Now what: Now shareholders wait patiently for the phase 3 data on how this antibiotic performs in complicated intra-abdominal infections, which could be a much bigger market. It could also have applications in an even broader sense with treating hospital-acquired/ventilator-associated bacterial pneumonia, which it's also aiming to treat with experimental compound tedizolid phosphate. It's certainly an exciting time to be a Cubist shareholder and it's quite possible that a number of new compounds from its pipeline could be approved if things keep going its way. I would certainly suggest keeping Cubist on your watchlist moving forward.

The growth opportunity you won't want to miss
Cubist is definitely giving shareholders a lot of hope for future revenue growth-but so is this incredible tech stock which is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this company will be a huge winner in 2013 and beyond. Just click here to watch!


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2742457, ~/Articles/ArticleHandler.aspx, 9/18/2014 3:57:49 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement